Steve Potts

Steve Potts, PhD, MBA

Cofounder, CEO & Director

Steve Potts, PhD, MBA (Cofounder & CEO) leads OncoMyx. Steve has worked in the biopharma industry since 1999 and has had experience in a wide range of areas, including product development, sales, marketing, and general management. He has a proven track record of success, with his last three companies all with significant shareholder returns. He was Vice President of Medical Affairs at Ignyta, which was acquired by Roche for $1.7B, and he led the global operation of the testing of 30,000 patients in an oncology basket trial for entrectinib in 15 countries. The molecule was the first in industry to receive breakthrough designation equivalents in the USA, Europe, and Japan. Prior to Ignyta, he bootstrapped his first company as founding CEO, Flagship Biosciences, to 75 employees and an exit for his investors. He was General Manager Life Sciences at Aperio, which exited to Danaher for $180M. He also built the Bioinformatics Department for a Fortune 500 Company, Quest Diagnostics, which subsequently delivered $1B of annual revenue. He earned a BS in Physics from Wheaton College, Illinois and PhD in Biological Engineering and MBA from the University of California Davis.

Leslie Sharp

Leslie Sharp, PhD

Chief Scientific Officer

Leslie Sharp, PhD (CSO) leads scientific activities and development of IND candidates. Trained as an immunologist, Leslie joined the immuno-oncology team at Pfizer, where she spent five years in progressively expanding areas of responsibility in the design and development of IO biologics. She has worked on multiple discovery oncology drug programs in pharmaceutical and biotech settings including GNF (Novartis), BioAtla, and CYBIOS. She is an accomplished scientific and strategic leader with extensive experience in drug discovery and development. She has a strong track record of building high performing teams and delivering results and is a highly motivated leader capable of effectively working in dynamic multi-disciplinary teams. She earned a BS from University of Utah and PhD in Biology from University of California, San Diego.


Robert F. Williamson, III

Chief Business and Financial Officer

Mr. Williamson has more than two decades of experience in building, financing, and leading private and public biotechnology companies through critical phases of growth. Prior to joining OncoMyx, he was the Chief Executive Officer of BioTheryX, a protein degradation therapeutics company, where he raised a $100 million crossover round and positioned the company for an initial public offering. Prior to joining BioTheryX, Mr. Williamson served as Chief Executive Officer of both PharmAkea (acquired by Galecto) and ATXCo (acquired by Blade Therapeutics), oncology and fibrosis drug development companies financed through a partnership with Celgene. Prior to those companies, Mr. Williamson was Chief Executive Officer of Arriva Pharmaceuticals, President and Chief Operating Officer of Eos Biotechnology (acquired by Protein Design Labs), and Chief Operating Officer of DoubleTwist (acquired in part by Merck and Hitachi). Notably, Mr. Williamson served as an early Director of Pharmasset, where he helped finance, grow, and advance the company into the public markets and through its acquisition by Gilead in 2011 for $11 billion. Prior to his management roles in industry, Mr. Williamson was a partner with The Boston Consulting Group and was a research assistant for the Federal Reserve Board.  He received a BA in economics from Pomona College and an MBA from the Stanford Graduate School of Business.


Jamie Doran, MSc, DABT, ERT

Vice President of Operations

Jamie Doran, M.Sc., DABT, ERT, leads cross-functional program management and operations at OncoMyx. Jamie has nearly 20 years experience in the biotech and pharmaceutical industry, with progress responsibility and proven track-record of successful cross-functional leadership and management of global product registrations. She has managed more than a hundred projects and has been responsible for cross-functional team management and monitoring of multi-million-dollar budgets and multi-year programs. Jamie has a unique background in preclinical program management and very strong scientific expertise that she gained in her roles in the biotechnology industry as well as in consulting to clients in pharmaceutical, biotech, and medical device industries. She has been accountable for the full scope of drug development programs (including regulatory strategy, R&D, and clinical testing) for small molecules and advanced therapeutics and is thus thoroughly versed in all aspects of lifecycle management for pharmaceutics and products of biotechnology. As a consultant to the industry for several years, Jamie provided expert advice in drug development, including strategic advice, gap analyses, program planning, and program management for novel compounds as well as second-generation products. She has extensive experience with designing, implementing, and critically evaluating IND-enabling programs as well as review and preparation of regulatory packages for new drug and biologic submissions. Her most recent tenure was a founding member of the Executive team (VP, Drug Development) at Appili Therapeutics Inc. (XTSE: APLI), a development company focused on treatment and prevention of infectious disease. Jamie holds a Bachelor’s of Science from University of Western Ontario in Pharmacology and Toxicology and a Master’s of Science from Purdue University in Medicinal Chemistry and Molecular Pharmacology. Ms. Doran is a Diplomat of the American Board of Toxicology and is a European Registered Toxicologist with the Institute of Biology & British Toxicology Society (London, United Kingdom).


Danya Norton

Vice President of People

Danya Norton leads the People & Culture function for OncoMyx. Danya has spent her career working in the field organization effectiveness to unleash the potential of individuals and drug discovery teams. She has more than 17 years of experience of partnering with drug discovery teams in both the global pharmaceutical and biotech startup environments to drive innovative cultures where science and strategy thrive. Prior to joining OncoMyx, Danya was a co-founder of Agate Partners where she partnered with early biotech start-ups to define and align their strategy, culture and leadership development programs.  She held the role of Vice President of People & Culture at Human Longevity as well as at the Novartis Institute for BioMedical Research (NIBR), and Novartis Institute for Functional Genomics (GNF).



James Burke

James Burke, MD

Medical Advisor

James Burke, MD (Medical Advisor) advises the company on clinical development. James has advised Turnstone Biologics, served as Chief Medical Officer at Sillajen Biotherapeutics and Vice President of Clinical Research at Jennerex. James oversaw global clinical development for Sillajen including design and oversight of clinical trials of gene and immunotherapy agents for hepatocellular carcinoma (now in Phase 3), renal cell carcinoma, colorectal cancer, and various other solid tumors. James has over 15 years of preclinical and clinical experience in the field of gene and immunotherapy including work with various oncolytic virus platforms, tumor vaccines, and other gene therapy related agents. Prior to SillaJen and Jennerex, he was Associate Director of Clinical Research at Cell Genesys and Director of Clinical Research at a regional cancer center. James earned a BS in Biochemistry from University of California, San Diego and MD from Georgetown University. He completed a general internal medicine residency at University of California, San Diego followed by a Hematology-Oncology Fellowship at University of California, San Francisco. James is Board Certified in both Hematology and Oncology.

George Roth

Georg Roth, PhD

CMC Advisor

Georg Roth, PhD (CMC Advisor) advises the company on manufacturing. Georg served as Chief Operating Officer and Senior Vice President of Technical Operations at SillaJen Biotherapeutics, where he was responsible for managing U.S. operations and heading all technical functions for the development of oncolytic viruses. Prior to SillaJen, he worked as Vice President of Technical Operations at Jennerex, with responsibilities in process development, analytical development, and manufacturing of oncolytic viruses. Georg was Director of Technical Affairs at Dynavax and also established an international consulting company specializing in bioprocess technology. He also held positions of increasing responsibility at Berlex Laboratories. Altogether Georg has over 30 years of experience in the pharmaceutical industry. Georg earned a diploma and PhD in Chemical Engineering from Technical University Berlin, Germany.

Matt Fust

Matt Fust, MBA

Finance Advisor

Matt Fust, MBA (Finance Advisor) advises the company on financial matters. He is currently a board member and advisor to life sciences companies. Matt retired as Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, where he served through its acquisition by Amgen. Matt served as Chief Financial Officer at Jazz Pharmaceuticals and Perlegen Sciences. Previously, he was Senior Vice President and Chief Financial Officer at ALZA Corporation. Matt serves on the board of directors of the following publicly traded companies: Crinetics, Dermira, Atara, MacroGenics, and Ultragenyx. Matt previously served on the board of directors at Sunesis Pharmaceuticals. Matt earned a BA from University of Minnesota and MBA from Stanford University.

John Wallen

John Wallen, JD, PhD

Intellectual Property Advisor

John Wallen, JD, PhD (Intellectual Property Advisor) advises the company on intellectual property matters. John specializes in creating and helping to execute the IP strategy for emerging biotech companies. He is currently VP of Intellectual Property at Avidity Biosciences and an advisor at Crinetics Pharmaceuticals and Vividion Therapeutics. Previously, he held the position of Vice President, Intellectual Property & Corporate Legal at Ambrx. John was a partner in the Technology/Intellectual Property, Life Sciences, and Patent Litigation groups of the law firm Preston Gates & Ellis LLP in San Diego. John served as a patent attorney in the law department of Johnson & Johnson. He worked for Merck, serving first as a scientist and then as a patent agent. John is a patent attorney registered with the US Patent and Trademark Office. John earned a BS in Biology from State University of New York College at Oswego, MS in Clinical Microbiology from Long Island University, JD from Seton Hall Law School, and PhD in Molecular Biology from University of Pennsylvania.